Short Interest in Alphatec Holdings, Inc. (NASDAQ:ATEC) Expands By 7.8%

Alphatec Holdings, Inc. (NASDAQ:ATEC) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 11,420,000 shares, an increase of 7.8% from the November 15th total of 10,590,000 shares. Based on an average daily volume of 2,120,000 shares, the short-interest ratio is presently 5.4 days.

Institutional Investors Weigh In On Alphatec

Several institutional investors have recently made changes to their positions in ATEC. Van ECK Associates Corp lifted its position in shares of Alphatec by 11.8% in the 2nd quarter. Van ECK Associates Corp now owns 12,275 shares of the medical technology company’s stock worth $128,000 after purchasing an additional 1,300 shares during the period. Atria Investments Inc increased its position in shares of Alphatec by 8.0% in the third quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock worth $109,000 after purchasing an additional 1,460 shares during the last quarter. Cetera Advisors LLC lifted its stake in Alphatec by 15.6% in the first quarter. Cetera Advisors LLC now owns 12,720 shares of the medical technology company’s stock worth $175,000 after purchasing an additional 1,720 shares during the last quarter. Comerica Bank boosted its holdings in Alphatec by 64.8% in the first quarter. Comerica Bank now owns 6,443 shares of the medical technology company’s stock valued at $89,000 after acquiring an additional 2,534 shares in the last quarter. Finally, Entropy Technologies LP increased its stake in shares of Alphatec by 14.9% during the third quarter. Entropy Technologies LP now owns 21,623 shares of the medical technology company’s stock valued at $120,000 after purchasing an additional 2,800 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors.

Alphatec Trading Down 0.8 %

Shares of Alphatec stock traded down $0.08 during trading on Friday, hitting $9.62. 771,119 shares of the company were exchanged, compared to its average volume of 1,926,179. The firm’s fifty day moving average price is $7.98 and its 200 day moving average price is $8.14. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The firm has a market capitalization of $1.36 billion, a P/E ratio of -7.52 and a beta of 1.38. Alphatec has a 1-year low of $4.88 and a 1-year high of $17.34.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ATEC shares. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price target on shares of Alphatec in a research report on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and set a $13.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Lake Street Capital cut their target price on Alphatec from $32.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Thursday, October 31st. Finally, Barclays raised their price target on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 19th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $17.11.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.